Sign inJoin waitlistJoin the waitlist

Thorsten Leucker

Program Director, Cardiovascular Disease Fellowship · Johns Hopkins University School of Medicine

Credentials: · · · ·

History

Cardiovascular Disease Fellowship · Johns Hopkins University School of Medicine
Present
Johns Hopkins University School of Medicine
Present

Cardiovascular Disease
Johns Hopkins University School of Medicine
2014–2017
Internal Medicine
University of Louisville School of Medicine
2011–2014
Doctor of Medicine
2004–2008

Research

Inflammation and cardiovascular disease: From mechanisms to therapeutics
Review · American Journal of Preventive Cardiology · 2020 · 362 citations
Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy
Circulation · 2007 · 253 citations
Coronary heart disease risk: Low-density lipoprotein and beyond
Review · Trends in Cardiovascular Medicine · 2022 · 173 citations

Gary Gerstenblith
32 papers
Tarek Harb
23 papers · 11 as a resident
EZ
Efthymios Ziogos
16 papers · 8 as a resident
Allison Hays
13 papers
Thomas Schindler
11 papers · 9 as a fellow
Michael Blaha
9 papers
Roger Blumenthal
8 papers
Seth Martin
8 papers
MV
Michael Vavuranakis
7 papers · 5 as a resident
Todd Brown
7 papers
Anum Minhas
6 papers
Mark Atallah
6 papers · 5 as a resident

Grants

Lipoprotein (a) Modification of the Impact of HIV Infection on Atherosclerotic Cardiovascular Disease
National Heart, Lung, and Blood Institute · R01
Contact PI · $2.1M · Johns Hopkins University
2024–2029
Addressing the Continuing Challenge of Identifying and Managing Coronary Risk: A Person-Specific Strategy Using Proteomics
National Heart, Lung, and Blood Institute · R43
PI · $295.2K · Proteas Bioanalytics Inc.
2022–2024

Clinical trials

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
Principal investigator · Completed · Phase 2
Johns Hopkins University
2023–2025
Evolocumab in Patients With Acute MI
Principal investigator · Completed · Phase 2
Johns Hopkins University
2019–2024
Evolocumab in Acute Coronary Syndrome
Principal investigator · Completed · Phase 2
Johns Hopkins University
2018–2025
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2030